{"id":"https://openalex.org/W7225326283","doi":"https://doi.org/10.1136/jitc-2026-sitc2026.0566","title":"566 OBX-115 TIL cell therapy in ICI-resistant advanced melanoma: pooled safety and updated efficacy with minimally invasive tumor tissue procurement, low-dose lymphodepletion, and IL2-free regimen","display_name":"566 OBX-115 TIL cell therapy in ICI-resistant advanced melanoma: pooled safety and updated efficacy with minimally invasive tumor tissue procurement, low-dose lymphodepletion, and IL2-free regimen","publication_year":2026,"publication_date":"2026-11-01","ids":{"openalex":"https://openalex.org/W7225326283","doi":"https://doi.org/10.1136/jitc-2026-sitc2026.0566"},"language":"en","primary_location":{"id":"doi:10.1136/jitc-2026-sitc2026.0566","doi":"https://doi.org/10.1136/jitc-2026-sitc2026.0566","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2026-sitc2026.0566","pdf_url":"https://jitc.bmj.com/content/14/Suppl_2/A634.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular Abstracts","raw_type":"proceedings-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://jitc.bmj.com/content/14/Suppl_2/A634.full.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5029017725","display_name":"Rodabe Navroze Amaria","orcid":"https://orcid.org/0000-0001-6876-278X","observed_orcids":["https://orcid.org/0000-0001-6876-278X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rodabe N Amaria","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5159553428","display_name":"Allison Betof","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210137306","display_name":"Stanford Medicine","ror":"https://ror.org/03mtd9a03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]},{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Allison Betof","raw_affiliation_strings":["Stanford University School of Medicine, Stanford, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Stanford University School of Medicine, Stanford, CA, USA","institution_ids":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001155783","display_name":"Gino Kim In","orcid":"https://orcid.org/0000-0002-7060-5123","observed_orcids":["https://orcid.org/0000-0002-7060-5123"]},"institutions":[{"id":"https://openalex.org/I4210117038","display_name":"USC Norris Comprehensive Cancer Center","ror":"https://ror.org/01nmyfr60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800154431","https://openalex.org/I4210117038"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gino K In","raw_affiliation_strings":["USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA","institution_ids":["https://openalex.org/I4210117038"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040291209","display_name":"Alexander Noor Shoushtari","orcid":"https://orcid.org/0000-0002-8065-4412","observed_orcids":["https://orcid.org/0000-0002-8065-4412"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alexander N Shoushtari","raw_affiliation_strings":["Memorial Sloan Kettering Cancer Center, New York City, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan Kettering Cancer Center, New York City, NY, USA","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060606996","display_name":"Yazan Samhouri","orcid":"https://orcid.org/0000-0003-0271-4798","observed_orcids":["https://orcid.org/0000-0003-0271-4798"]},"institutions":[{"id":"https://openalex.org/I4387154023","display_name":"Banner MD Anderson Cancer Center","ror":"https://ror.org/049c9q337","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2802412784","https://openalex.org/I4387154023"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yazan Samhouri","raw_affiliation_strings":["Banner MD Anderson Cancer Center, Gilbert, AZ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Banner MD Anderson Cancer Center, Gilbert, AZ, USA","institution_ids":["https://openalex.org/I4387154023"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086435569","display_name":"Tirrell T. Johnson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I147878501","display_name":"Orlando Health","ror":"https://ror.org/0488cct49","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I147878501"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tirrell T Johnson","raw_affiliation_strings":["Orlando Health Cancer Institute, Orlando, FL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Orlando Health Cancer Institute, Orlando, FL, USA","institution_ids":["https://openalex.org/I147878501"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028592995","display_name":"Omid Hamid","orcid":"https://orcid.org/0000-0002-8238-4655","observed_orcids":["https://orcid.org/0000-0002-8238-4655"]},"institutions":[{"id":"https://openalex.org/I4210104507","display_name":"Angeles Clinic and Research Institute","ror":"https://ror.org/01ct2ab72","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1282927834","https://openalex.org/I4210104507"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Omid Hamid","raw_affiliation_strings":["The Angeles Clinic and Research Institute, a Cedars Sinai Affiliate, Los Angeles, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Angeles Clinic and Research Institute, a Cedars Sinai Affiliate, Los Angeles, CA, USA","institution_ids":["https://openalex.org/I4210104507"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070576000","display_name":"Georgina Venetia Long","orcid":"https://orcid.org/0000-0001-8894-3545","observed_orcids":["https://orcid.org/0000-0001-8894-3545"]},"institutions":[{"id":"https://openalex.org/I129604602","display_name":"The University of Sydney","ror":"https://ror.org/0384j8v12","country_code":"AU","type":"education","lineage":["https://openalex.org/I129604602"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Georgina V Long","raw_affiliation_strings":["Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia","institution_ids":["https://openalex.org/I129604602"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5137149673","display_name":"Michael Davies","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Davies","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000768609","display_name":"Hussein A. Tawbi","orcid":"https://orcid.org/0000-0003-1942-851X","observed_orcids":["https://orcid.org/0000-0003-1942-851X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hussein A Tawbi","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114002330","display_name":"Isabella C. Glitza","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Isabella C Glitza","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077265672","display_name":"Jennifer Leigh McQuade","orcid":"https://orcid.org/0000-0002-2393-2172","observed_orcids":["https://orcid.org/0000-0002-2393-2172"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jennifer L McQuade","raw_affiliation_strings":["JMQ Oncology Advisors LLC, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"JMQ Oncology Advisors LLC, Houston, TX, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5160980313","display_name":"Parameswaran N Hari","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Parameswaran N Hari","raw_affiliation_strings":["Obsidian Therapeutics, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Obsidian Therapeutics, Cambridge, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003442518","display_name":"Giridharan Ramsingh","orcid":"https://orcid.org/0000-0003-0706-3584","observed_orcids":["https://orcid.org/0000-0003-0706-3584"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Giridharan Ramsingh","raw_affiliation_strings":["Obsidian Therapeutics, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Obsidian Therapeutics, Cambridge, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114186505","display_name":"Giri Sulur","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Giri Sulur","raw_affiliation_strings":["Obsidian Therapeutics, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Obsidian Therapeutics, Cambridge, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017818371","display_name":"Raina Duan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Raina Duan","raw_affiliation_strings":["Obsidian Therapeutics, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Obsidian Therapeutics, Cambridge, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112990438","display_name":"Ricky Rudraraju","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ricky Rudraraju","raw_affiliation_strings":["Obsidian Therapeutics, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Obsidian Therapeutics, Cambridge, MA, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5086165685","display_name":"Jason Alan Chesney","orcid":"https://orcid.org/0000-0003-0217-8278","observed_orcids":["https://orcid.org/0000-0003-0217-8278"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jason A Chesney","raw_affiliation_strings":["UofL Health \u2013 Brown Cancer Center, Louisville, KY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UofL Health \u2013 Brown Cancer Center, Louisville, KY, USA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":9,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2490,"currency":"USD","value_usd":2490},"apc_paid":{"value":2490,"currency":"USD","value_usd":2490},"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"A634","last_page":"A634"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.6161999702453613,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.6161999702453613,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.319599986076355,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.038100000470876694,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tumor-infiltrating-lymphocytes","display_name":"tumor-infiltrating lymphocytes","score":0.9120000004768372},{"id":"https://openalex.org/keywords/advanced-melanoma","display_name":"advanced melanoma","score":0.7889999747276306},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitor-resistance","display_name":"immune checkpoint inhibitor resistance","score":0.9769999980926514},{"id":"https://openalex.org/keywords/acetazolamide","display_name":"acetazolamide","score":0.9079999923706055},{"id":"https://openalex.org/keywords/core-needle-biopsy","display_name":"core needle biopsy","score":0.8730000257492065},{"id":"https://openalex.org/keywords/immune-effector-cell-associated-neurotoxicity-syndrome","display_name":"immune effector cell-associated neurotoxicity syndrome","score":0.5730000138282776},{"id":"https://openalex.org/keywords/cytokine-release-syndrome","display_name":"cytokine release syndrome","score":0.7770000100135803},{"id":"https://openalex.org/keywords/hematological-toxicity","display_name":"hematologic toxicity","score":0.6380000114440918},{"id":"https://openalex.org/keywords/treatment-safety","display_name":"treatment safety","score":0.3790000081062317},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.6650000214576721},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.4970000088214874}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9569000005722046},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.6370999813079834},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4918999969959259},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4903999865055084},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.42879998683929443},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.41269999742507935},{"id":"https://openalex.org/C2780850621","wikidata":"https://www.wikidata.org/wiki/Q3961647","display_name":"Cytokine release syndrome","level":5,"score":0.4077000021934509},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.38510000705718994},{"id":"https://openalex.org/C2775934546","wikidata":"https://www.wikidata.org/wiki/Q179991","display_name":"Biopsy","level":2,"score":0.335099995136261},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.32249999046325684},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.31700000166893005},{"id":"https://openalex.org/C10882517","wikidata":"https://www.wikidata.org/wiki/Q15268054","display_name":"Cell therapy","level":3,"score":0.30399999022483826},{"id":"https://openalex.org/C2777334693","wikidata":"https://www.wikidata.org/wiki/Q659446","display_name":"Maximum tolerated dose","level":3,"score":0.2581000030040741},{"id":"https://openalex.org/C2777405951","wikidata":"https://www.wikidata.org/wiki/Q413690","display_name":"Acetazolamide","level":2,"score":0.2549999952316284},{"id":"https://openalex.org/C2778300832","wikidata":"https://www.wikidata.org/wiki/Q1589604","display_name":"Premedication","level":2,"score":0.2533000111579895}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1136/jitc-2026-sitc2026.0566","doi":"https://doi.org/10.1136/jitc-2026-sitc2026.0566","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2026-sitc2026.0566","pdf_url":"https://jitc.bmj.com/content/14/Suppl_2/A634.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular Abstracts","raw_type":"proceedings-article"}],"best_oa_location":{"id":"doi:10.1136/jitc-2026-sitc2026.0566","doi":"https://doi.org/10.1136/jitc-2026-sitc2026.0566","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2026-sitc2026.0566","pdf_url":"https://jitc.bmj.com/content/14/Suppl_2/A634.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular Abstracts","raw_type":"proceedings-article"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7225326283.pdf","grobid_xml":"https://content.openalex.org/works/W7225326283.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4393983616","https://openalex.org/W4410816802","https://openalex.org/W4400272419","https://openalex.org/W4393988663","https://openalex.org/W7162524651","https://openalex.org/W4410818559","https://openalex.org/W7133664945","https://openalex.org/W4399579617","https://openalex.org/W4409821728","https://openalex.org/W7225337269"],"abstract_inverted_index":{"Background":[0],"OBX-115":[1,66,100,313,391,454],"tumor-infiltrating":[2,429,456],"lymphocytes":[3],"(TIL)":[4,431,458],"are":[5],"engineered":[6,428,455],"to":[7,295],"express":[8],"acetazolamide":[9],"(ACZ)-regulatable":[10],"membrane-bound":[11,463],"IL15":[12,464],"(mbIL15),":[13],"abrogating":[14],"the":[15,42,64,150,394,518,521],"need":[16,397],"for":[17],"systemic":[18],"IL2":[19,114,329],"and":[20,45,61,107,128,162,199,326,342,357,360,376,384,403,493,513,532],"demonstrating":[21],"a":[22],"favorable":[23,385],"safety":[24,526,531],"profile":[25],"with":[26,70,159,214,257,330,365,380,436,461,468,517],"promising":[27,381],"efficacy":[28,62],"in":[29,68,137,168,288,302,374,398,434,466,515],"immune":[30,437,475],"checkpoint":[31,438,476],"inhibitor":[32,439],"(ICI)-resistant":[33,440],"advanced":[34,72,400,469],"melanoma.":[35,73,444],"1":[36,44,303,511],"2":[37,153,249,251,426,480],"We":[38],"report":[39],"outcomes":[40],"across":[41,126],"phase":[43,46,152,479],"1/2":[47],"trial":[48],"experience.Methods":[49],"Two":[50],"single-arm":[51],"open-label":[52],"trials":[53],"(single-center,":[54],"NCT05470283;":[55],"multicenter,":[56],"NCT06060613)":[57,496],"explored":[58],"dosing,":[59],"safety,":[60,386],"of":[63,118,164,265,281,328,362,371,520,523],"investigational":[65],"regimen":[67,373],"patients":[69,123,140,144,190,201,238,252,435,467,536],"ICI-resistant":[71,399],"Patients":[74],"underwent":[75],"tumor":[76],"tissue":[77],"procurement":[78],"(TTP)":[79],"by":[80,95,408,500],"core":[81],"needle":[82],"biopsy":[83],"(CNB;":[84],"18-gauge":[85],"needle,":[86],"\u2265":[87,181],"4-cm":[88],"cumulative":[89],"length)":[90],"or":[91,97,223,229,442,503],"surgical":[92],"excision,":[93],"followed":[94],"low-":[96],"standard-dose":[98,171],"lymphodepletion,":[99,158,325],"infusion":[101],"(per-protocol":[102,110],"escalating":[103,111],"maximum":[104],"cell":[105,315,432,459],"doses),":[106],"oral":[108],"ACZ":[109,195,204],"doses/schedules).":[112],"No":[113,131,232],"was":[115,196,211,246,273,300,406],"administered.Result":[116],"As":[117],"05":[119],"May":[120],"2026,":[121],"37":[122],"were":[124,134,354,498],"treated":[125,239,308],"studies":[127,497],"dose":[129,154],"levels.":[130],"TTP-related":[132],"TEAEs":[133,166,353,364],"reported,":[135],"including":[136,146,284,321],"10":[138,282],"(27.0%)":[139],"undergoing":[141],"CNB.":[142],"Twenty-six":[143],"(70.3%,":[145],"all":[147],"15":[148,237],"receiving":[149,170],"recommended":[151],"[RP2D])":[155],"received":[156,191,203],"low-dose":[157,193,324,366],"lower":[160],"rates":[161,359],"severity":[163,361],"hematologic":[165,363],"than":[167],"those":[169],"lymphodepletion":[172,367],"(all-grade,":[173],"69.2%":[174],"vs":[175,184],"100%,":[176,185],"p":[177,186],"=":[178,187],"0.038;":[179],"Grade":[180,218,225],"3,":[182],"65.4%":[183],"0.025).":[188],"Four":[189],"outpatient":[192],"lymphodepletion.":[194],"well-tolerated":[197],"overall,":[198,356],"30":[200],"(81.1%)":[202],"redosing":[205],"(all":[206],"outpatient).":[207],"ACZ-induced":[208],"mbIL15":[209],"expression":[210],"not":[212],"associated":[213],"ICANS,":[215],"capillary":[216],"leak,":[217],"4":[219],"cytokine":[220],"release":[221],"syndrome":[222],"other":[224],"\u22653":[226],"immune-related":[227],"TEAEs,":[228],"treatment-related":[230],"mortality.":[231],"patient":[233,340],"required":[234],"ICU":[235],"transfer.Among":[236],"at":[240,290,507],"RP2D,":[241],"confirmed":[242,258],"ORR":[243],"(RECIST":[244],"v1.1)":[245],"67%":[247],"(10/15,":[248],"CR);":[250],"had":[253,306],"CNB":[254,322,335],"TTP,":[255,323],"both":[256,285],"response.":[259],"At":[260],"median":[261,269],"(range)":[262],"study":[263],"follow-up":[264],"8.3":[266],"months":[267,275],"(4.1\u201321.4),":[268],"(95%":[270],"CI)":[271],"PFS":[272],"8.1":[274],"(3.9-not":[276],"estimable)":[277],"after":[278],"infusion;":[279],"6":[280],"responders,":[283],"CRs,":[286],"remained":[287],"response":[289,382],"last":[291],"assessment":[292],"(range,":[293],"2.8+":[294],"17.9+":[296],"months).":[297],"CNS":[298,310],"progression":[299],"observed":[301],"patient,":[304],"who":[305],"prior":[307],"symptomatic":[309],"disease.Conclusions":[311],"Investigational":[312],"TIL":[314],"therapy":[316,460],"demonstrates":[317],"meaningful":[318],"patient-centric":[319],"benefits,":[320],"replacement":[327],"ACZ-regulatable":[331],"mbIL15.":[332],"Minimally":[333],"invasive":[334],"TTP":[336],"may":[337,392],"enable":[338],"broader":[339],"eligibility":[341],"facilitate":[343],"sampling":[344],"from":[345],"multiple":[346],"lesions,":[347],"while":[348],"maintaining":[349],"antitumor":[350],"activity.":[351],"Immune-related":[352],"infrequent":[355],"reduced":[358],"support":[368],"continued":[369],"evaluation":[370],"this":[372],"ongoing":[375],"future":[377],"studies.":[378],"Together":[379],"durability":[383],"these":[387],"findings":[388],"suggest":[389],"that":[390,471],"address":[393],"unmet":[395],"medical":[396],"melanoma.Acknowledgements":[401],"Editorial":[402],"writing":[404],"assistance":[405],"provided":[407,537],"Amanda":[409],"M":[410],"Kelly":[411],"(Obsidian":[412],"Therapeutics,":[413],"Inc.).Trial":[414],"Registration":[415],"Clinicaltrials.gov:":[416],"NCT05470283,":[417],"NCT06060613References":[418],"Amaria":[419],"RN,":[420],"et":[421,452],"al.":[422,453],"OBX-115,":[423],"an":[424],"interleukin":[425],"(IL2)-sparing":[427],"lymphocyte":[430,457],"therapy,":[433],"unresectable":[441],"metastatic":[443],"J":[445,482],"Clin":[446,483],"Oncol.":[447,484],"2024;42(Suppl":[448],"16):Abstract":[449,486],"9515.Betof":[450],"A,":[451],"regulatable":[462],"(mbIL15)":[465],"melanoma":[470],"has":[472],"progressed":[473],"on/after":[474],"inhibitors":[477],"(ICI):":[478],"results.":[481],"2026;44(Suppl":[485],"9507.Ethics":[487],"Approval":[488],"The":[489],"first-in-human":[490],"(Clinicaltrials.gov:":[491,495],"NCT05470283)":[492],"Agni-01":[494],"approved":[499],"local":[501],"institutional":[502],"central":[504],"review":[505,527],"boards":[506,528],"9":[508],"sites":[509],"(FIH,":[510],"site)":[512],"conducted":[514],"accordance":[516],"principles":[519],"Declaration":[522],"Helsinki;":[524],"independent":[525],"monitored":[529],"overall":[530],"dose-optimization":[533],"decisions.":[534],"All":[535],"written":[538],"informed":[539],"consent.":[540]},"counts_by_year":[],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2026-11-06T00:00:00"}